Published in:
01-04-2022 | Metastasis | Research Letter
ACTH-secreting pituitary carcinoma with TP53, NF1, ATRX and PTEN mutations Case report and review of the literature
Authors:
Piotr Sumislawski, Roman Rotermund, Silke Klose, Anne Lautenbach, Annika K. Wefers, Celina Soltwedel, Behnam Mohammadi, Frank Jacobsen, Christian Mawrin, Jörg Flitsch, Wolfgang Saeger
Published in:
Endocrine
|
Issue 1/2022
Login to get access
Excerpt
Pituitary carcinoma (PC) is a very rare tumor entity of the sella turcica, representing 0.1–0.5% of all PitNETs tumors [
1‐
5]. Based on the WHO Classification, it is defined as pituitary tumor with confirmed craniospinal and/or systemic metastases [
6]. Most of them present CNS only (45,2%) or extra CNS (38,7%) metastases. Synchronous extra- and CNS metastases are less common (16,1%) [
7]. It is not known whether the tumors develop predominantly from PitNETs after a longer clinical course or de novo [
8]. PCs can be hormonally inactive or active (ACTH-, PRL-, GH-, TSH- FSH-, LH-secreting), but far most of them are ACTH- or PRL-secreting tumors [
8,
9]. There is little known about the genetic background of this tumor entity, because most of the information comes from case reports and singular larger case series.
ATRX [
10,
11]
, CDKN2A [
11]
, CDKN2B [
11]
, SDHB [
12],
TP53 [
11,
13] mutations have been identified in primary [
13] and
ATRX [
10,
11]
, CDKN2A [
11]
, CDKN2B [
11]
, H-Ras [
14] mutations in metastatic tumors.
MSH2 germline mutation was described in one case report [
15].
PTEN mutations were reported without localization [
16]. The tumors have a poor prognosis with a 66% mortality rate after 1 year and up to 80% after 8 years [
1,
17]. …